Cover Image
市場調查報告書

高三酸甘油脂血症 (hypertriglyceridemia):開發中產品分析

Hypertriglyceridemia - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363108
出版日期 內容資訊 英文 106 Pages
訂單完成後即時交付
價格
Back to Top
高三酸甘油脂血症 (hypertriglyceridemia):開發中產品分析 Hypertriglyceridemia - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 106 Pages
簡介

本報告提供高三酸甘油脂血症 (hypertriglyceridemia) 治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

高三酸甘油脂血症 (hypertriglyceridemia)的概要

治療藥的開發

  • 開發中產品的概要

高三酸甘油脂血症 (hypertriglyceridemia):企業開發中的治療藥

高三酸甘油脂血症 (hypertriglyceridemia):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

高三酸甘油脂血症 (hypertriglyceridemia):企業開發中的產品

高三酸甘油脂血症 (hypertriglyceridemia的)治療藥的開發企業

  • AbbVie Inc.
  • Alteogen Inc.
  • Biocon Limited
  • Coherus BioSciences, Inc.
  • Epirus Biopharmaceuticals, Inc.
  • Johnson & Johnson
  • Mabion SA
  • Marathon Pharmaceuticals, LLC
  • Momenta Pharmaceuticals, Inc.
  • Mycenax Biotech Inc.
  • Novartis AG
  • Oncobiologics, Inc.
  • Oncodesign SA
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Sandoz International GmbH
  • Swedish Orphan Biovitrum AB
  • Therapeutic Proteins International, LLC
  • UCB S.A.

高三酸甘油脂血症 (hypertriglyceridemia):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

高三酸甘油脂血症 (hypertriglyceridemia):暫停中的計劃

高三酸甘油脂血症 (hypertriglyceridemia):中止開發的產品

高三酸甘油脂血症 (hypertriglyceridemia):產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8175IDB

Summary

Global Markets Direct's, 'Hypertriglyceridemia - Pipeline Review, H1 2016', provides an overview of the Hypertriglyceridemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypertriglyceridemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertriglyceridemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hypertriglyceridemia
  • The report reviews pipeline therapeutics for Hypertriglyceridemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hypertriglyceridemia therapeutics and enlists all their major and minor projects
  • The report assesses Hypertriglyceridemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hypertriglyceridemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hypertriglyceridemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hypertriglyceridemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Hypertriglyceridemia Overview
  • Therapeutics Development
    • Pipeline Products for Hypertriglyceridemia - Overview
  • Hypertriglyceridemia - Therapeutics under Development by Companies
  • Hypertriglyceridemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hypertriglyceridemia - Products under Development by Companies
  • Hypertriglyceridemia - Companies Involved in Therapeutics Development
    • Acasti Pharma Inc.
    • Allergan Plc
    • Alnylam Pharmaceuticals, Inc.
    • Arisaph Pharmaceuticals, Inc.
    • AstraZeneca Plc
    • BASF SE
    • Cardax Pharmaceuticals, Inc.
    • Catabasis Pharmaceuticals, Inc.
    • CymaBay Therapeutics, Inc.
    • Jeil Pharmaceutical Co., Ltd.
    • Kyorin Pharmaceutical Co., Ltd.
    • Matinas BioPharma Holdings, Inc.
    • Pharmena SA
    • Sancilio & Company, Inc.
    • Thetis Pharmaceuticals LLC
    • Zydus Cadila Healthcare Limited
  • Hypertriglyceridemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AEM-28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AEM-2814 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALN-AC3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALN-ANG - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARI-3037MO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bezafibrate ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BioE-1115 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAT-2000 Series - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAT-2003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CDX-085 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gemcabene calcium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • icosabutate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISIS-APOCIIILRx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAT-9001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MBX-8025 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MN-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NKPL-66 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omega-3-carboxylic acids - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • saroglitazar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SC-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Hypertriglyceridaemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Dyslipidemia and Hypertriglyceridemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRIA-662 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • volanesorsen sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hypertriglyceridemia - Dormant Projects
  • Hypertriglyceridemia - Discontinued Products
  • Hypertriglyceridemia - Product Development Milestones
    • Featured News & Press Releases
      • May 16, 2016: Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen
      • Mar 23, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia
      • Feb 24, 2016: SPCI Announces US PTO Allowance of Patent Claims
      • Nov 18, 2015: Zydus announces clinical trials of Saroglitazar in patients with Severe Hypertriglyceridemia in USA
      • Jul 29, 2015: Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine
      • May 25, 2015: Phase 2a Clinical Study of Icosabutate in Patients with Severe Hypertriglyceridemia
      • Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia
      • Mar 02, 2015: Acasti Receives Full Data for Phase II TRIFECTA Trial
      • Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results
      • Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C
      • Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014
      • Jul 24, 2014: Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston
      • May 06, 2014: FDA Approves EPANOVA for the Treatment of Adults with Severe Hypertriglyceridemia
      • Mar 31, 2014: Catabasis to Present CAT-2003 Data at the American College of Cardiology's 63rd Annual Scientific Session
      • Dec 05, 2013: Catabasis Initiates Phase 2 Trial of CAT-2003 in Patients with Severe Hypertriglyceridemia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hypertriglyceridemia, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Hypertriglyceridemia - Pipeline by Acasti Pharma Inc., H1 2016
  • Hypertriglyceridemia - Pipeline by Allergan Plc, H1 2016
  • Hypertriglyceridemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Hypertriglyceridemia - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016
  • Hypertriglyceridemia - Pipeline by AstraZeneca Plc, H1 2016
  • Hypertriglyceridemia - Pipeline by BASF SE, H1 2016
  • Hypertriglyceridemia - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016
  • Hypertriglyceridemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016
  • Hypertriglyceridemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016
  • Hypertriglyceridemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016
  • Hypertriglyceridemia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016
  • Hypertriglyceridemia - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016
  • Hypertriglyceridemia - Pipeline by Pharmena SA, H1 2016
  • Hypertriglyceridemia - Pipeline by Sancilio & Company, Inc., H1 2016
  • Hypertriglyceridemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2016
  • Hypertriglyceridemia - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Hypertriglyceridemia - Dormant Projects, H1 2016
  • Hypertriglyceridemia - Dormant Projects (Contd..1), H1 2016
  • Hypertriglyceridemia - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Hypertriglyceridemia, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top